Milan, 2 April 2025 – Laboratorio Farmaceutico SIT (“SIT”) announces the acquisition of the pharmaceutical product “DINTOINA“. This drug is a key reference for the management of generalized epilepsy, excluding petit mal and partial seizures.
Beyond the neurological field, DINTOINA also has clinical applications in the treatment of other conditions, confirming its proven efficacy across multiple therapeutic areas.
This acquisition marks a significant step in SIT’s growth strategy within the Central Nervous System (CNS) sector, expanding the pharmaceutical company’s portfolio.
With a presence in over 70 countries, SIT develops, manufactures, and markets more than 75 branded pharmaceutical products, as well as Medical Devices and Food Supplements. The company continues its path of innovation and development, strengthening its offering to meet the needs of patients and healthcare professionals with high-quality and reliable solutions.
De Berti Jacchia assisted SIT throughout all phases of the transaction, from structuring the agreement to its finalization, with a specialized team led by Partner Pietro Meda, supported by Associate Francesca Zironi. Intellectual property-related advisory aspects were handled by Partner Andrea Terragni and Associate Laura Bussoli.